Causal Roles of CLEC5A and ISG20 in Atherosclerosis Progress

2026-04-13

Causal Roles of CLEC5A and ISG20 in Atherosclerosis Progression

Study Background and Research Question

Atherosclerosis (AS) remains a leading cause of global morbidity and mortality, characterized by lipid deposition and chronic inflammation within arterial walls. While immune and genetic mechanisms are known contributors, the precise molecular factors driving plaque formation and progression are incompletely defined. Zhang et al. (2025) set out to systematically identify and validate molecular regulators of AS risk by integrating genetic association, gene expression, and functional studies, focusing on CLEC5A and ISG20 as candidate drivers of disease pathogenesis [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135].

Key Innovation from the Reference Study

The study's principal innovation lies in its multi-layered approach: combining large-scale Mendelian randomization (MR) with expression quantitative trait locus (eQTL) data to infer causality, and then linking these findings to experimental validation in both cellular and animal models. This integrated analytic pipeline allowed the authors to move beyond correlation, providing robust evidence for CLEC5A and ISG20 as causal contributors to AS risk [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135].

Methods and Experimental Design Insights

Zhang et al. began by mining the Gene Expression Omnibus (GEO) for datasets comparing gene expression profiles between AS patients and controls. Candidate genes, including CLEC5A and ISG20, were prioritized based on differential expression and immune function annotation. eQTL mapping was then used to link genetic variants to expression levels of these genes in relevant tissues. MR analysis served to test for a causal relationship between gene expression and AS risk—leveraging genetic variants as instrumental variables. Odds ratios for causal effects were estimated (CLEC5A: OR = 1.001, P = 0.047; ISG20: OR = 1.001, P = 0.030) [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135]. For experimental validation, the authors used two model systems:

Oxidized LDL (ox-LDL)-stimulated macrophages in vitro, to mimic the inflammatory environment of AS.
ApoE–/– mouse models, a well-established genetic model of atherosclerosis.

Gene and protein expression of ISG20 were quantified by RT-qPCR and Western blot, while its spatial localization in atherosclerotic lesions was examined by immunofluorescence co-staining and immunohistochemistry [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135].

Protocol Parameters

assay | dilution 1:100–1:500 | IHC-P | Optimized for sensitive detection of rabbit primary antibodies in paraffin sections | workflow_recommendation [source_link: https://www.apexbt.com/hyperfluortm-594-goat-anti-rabbit-igg-h-l-antibody.html]
assay | dilution 1:500–1:2000 | ICC/IF | Provides strong signal for immunocytochemistry and immunofluorescence | product_spec [source_link: https://www.apexbt.com/hyperfluortm-594-goat-anti-rabbit-igg-h-l-antibody.html]
assay | dilution 1:250–1:1000 | Flow cytometry | Recommended for robust detection of rabbit primary antibodies in FC | product_spec [source_link: https://www.apexbt.com/hyperfluortm-594-goat-anti-rabbit-igg-h-l-antibody.html]
assay | dilution dependent on conditions | ELISA | Flexibility for detection antibody optimization | product_spec [source_link: https://www.apexbt.com/hyperfluortm-594-goat-anti-rabbit-igg-h-l-antibody.html]

Core Findings and Why They Matter

The study identified significant upregulation of CLEC5A and ISG20 in AS patients versus controls, both at the transcript and protein levels. MR analysis revealed a positive causal relationship between increased expression of these genes and AS risk, with ISG20 in particular emerging as a key mediator. Functional enrichment analyses supported roles in immune activation, inflammatory signaling, and lipid metabolism regulation [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135]. Notably, in both ox-LDL-stimulated macrophages and ApoE–/– mice, ISG20 expression was robustly elevated (P < 0.01) [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135]. Immunohistochemical and immunofluorescence analyses revealed ISG20 localization in macrophage- and endothelial-rich regions of atherosclerotic plaques, directly implicating ISG20 in the cellular processes underpinning AS pathology. These results provide the first experimental evidence for ISG20 as a driver of macrophage lipid accumulation and inflammatory response, positioning it as a promising therapeutic target [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135].

Comparison with Existing Internal Articles

Recent internal articles, such as "Empowering Translational Discovery" and "Illuminating Atherosclerosis Mechanisms," provide strategic overviews of advanced immunofluorescence and multiplexed detection techniques for atherosclerosis research [source_type: workflow_recommendation][source_link: https://multi-colour-immunofluorescence.com/index.php?g=Wap&m=Article&a=detail&id=10929][source_link: https://amenamevircompounds.com/index.php?g=Wap&m=Article&a=detail&id=122]. These resources emphasize the value of high-specificity secondary antibodies, such as the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L), in enabling robust multi-marker analysis and enhancing reproducibility in workflows involving immunocytochemistry, immunohistochemistry, and flow cytometry. Zhang et al.'s work provides a specific mechanistic context in which such assay strategies are essential—for example, in spatially mapping ISG20 expression and validating its role in disease-relevant cell types.

Limitations and Transferability

While the integrated MR and eQTL approach strengthens causal inference, certain limitations persist. Genetic associations were drawn primarily from publicly available datasets, which may be subject to population stratification and bias [source_type: paper][source_link: https://doi.org/10.3389/fimmu.2025.1644135]. Functional validation focused on ISG20, with CLEC5A less extensively characterized at the experimental level. The translatability of findings from mouse models to human disease also requires further exploration. Additionally, while immunofluorescence and immunohistochemistry offer spatial resolution, quantitative limitations remain—underlining the importance of careful antibody validation and controls.

Research Support Resources

For researchers aiming to reproduce or extend these findings, robust detection of rabbit primary antibodies is essential in immunohistochemistry, immunocytochemistry (ICC/IF), flow cytometry (FC), and ELISA. The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K3305) from APExBIO provides a validated option for these applications, offering a fluorophore excitation maximum at 590 nm and emission at 617 nm [source_type: product_spec][source_link: https://www.apexbt.com/hyperfluortm-594-goat-anti-rabbit-igg-h-l-antibody.html]. By following recommended protocols and integrating multiplex immunolabeling strategies as outlined in internal guidance articles, researchers can achieve sensitive and specific detection necessary for mechanistic studies in atherosclerosis and related fields.